source
- Vir Biotechnology reports positive results for hepatitis D combo in first pivotal trialVir Biotechnology announced that its chronic hepatitis D treatment met its primary goal in the first of three late‑stage studies. The trial evaluated a once‑monthly combination therapy that include…
- FDA opens investigation into Novartis' Zolgensma after cancer cases reportedThe U.S. Food and Drug Administration announced on Friday that it is opening a formal investigation into the gene-therapy product Zolgensma, marketed by Novartis for spinal muscular atrophy. The a…